Drug Profile

RVx 2001

Alternative Names: RVx-2001

Latest Information Update: 10 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Southern Illinois University School of Medicine; University of Kansas
Developer Rational Vaccines
Class Attenuated vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 May 2026 RVx 2001 is still in preclinical development for Herpes simplex virus type-2 infections (Prevention) in USA (Rational Vaccines pipeline, May 2026)
28 Feb 2026 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in USA
19 Jan 2022 Preclinical trials in Herpes simplex virus type 2 infections (Prevention) in USA (Rational Vaccines pipeline, January 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com